Biogen INC Form 4 insider transactions

Biogen Inc. Director Jesus B. Mantas acquired 2,370 shares of the company's common stock on June 17, 2025, increasing his total beneficial ownership to 9,758 shares.

Biogen Inc. Director William A. Hawkins reported the acquisition of 2,370 shares of common stock, increasing his direct beneficial ownership to 8,860 shares.

Biogen Inc. Director Maria C. Freire has acquired 2,370 shares of common stock, increasing her beneficial ownership to 6,815 shares.

Biogen Inc. Director Eric K. Rowinsky has acquired 2,370 shares of common stock, increasing his beneficial ownership to 24,339 shares, as reported in a recent SEC Form 4 filing.

Biogen Inc. Director Stephen A. Sherwin acquired 2,370 shares of common stock on June 17, 2025, increasing his direct beneficial ownership to 13,688 shares.

Biogen Inc. Director Susan Langer has acquired 2,370 shares of common stock at a price of $0, increasing her direct beneficial ownership to 5,129.1 shares.

Biogen Inc. Director Caroline Dorsa acquired 3,160 shares of common stock at no cost, increasing her direct beneficial ownership to 31,002 shares.

Priya Singhal, Head of Development at Biogen Inc., reported the sale of 3,806 shares of common stock on May 19, 2025.

Adam Keeney, Head of Corporate Development at Biogen, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director Caroline Dorsa reported purchasing 1,235 shares of Biogen stock at $122.72 on May 2, 2025.

Chief Accounting Officer Sean Godbout reports acquiring common stock through an employee stock purchase plan and receiving restricted stock units.

Director Stephen Sherwin sold 8,760 shares of Biogen (BIIB) common stock at a price of $150.0162 on March 7, 2025.

Priya Singhal, Head of Development at Biogen, reports the vesting of restricted stock units and subsequent tax withholding.

Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, reports the vesting of restricted stock units and subsequent tax withholding.

EVP and CFO Michael McDonnell reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Robin Kramer, Chief Accounting Officer of Biogen, reports the vesting of restricted stock units and subsequent tax withholding.

EVP of Human Resources at Biogen, Gregory Ginger, reports the vesting and subsequent disposal of shares to cover tax obligations.

EVP and Chief Legal Officer of Biogen, Susan Alexander, reports the vesting and disposal of restricted stock units and common stock.

Rachid Izzar, Head of Global Product Strategy at Biogen, reports the acquisition of shares through the vesting of restricted stock units and subsequent disposition to cover tax obligations.

Rachid Izzar, Head of Global Product Strategy at Biogen, reports the acquisition and disposal of Biogen common stock and restricted stock units on February 7, 2025.

EVP and CFO Michael McDonnell reports the acquisition and disposal of Biogen stock and restricted stock units on February 7, 2025.

Biogen's CEO, Christopher Viehbacher, reports the acquisition and disposal of company stock and restricted stock units.

Jane Grogan, Head of Research at Biogen, reports the acquisition and disposal of common stock and restricted stock units.

Adam Keeney, Head of Corporate Development at Biogen, reports acquisition and disposal of common stock and restricted stock units.

Rachid Izzar, Head of Global Product Strategy at Biogen, reports the acquisition of 9,130 restricted stock units (RSUs) on February 6, 2025, vesting in equal yearly installments starting February 6, 2026.

Chief Accounting Officer Robin Kramer reported the acquisition and disposal of Biogen Inc. stock and restricted stock units on February 7, 2025.

Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, reports the acquisition and disposal of Biogen common stock and restricted stock units.

Priya Singhal, Head of Development at Biogen, reports acquisition and disposal of common stock and restricted stock units.

EVP of Human Resources at Biogen, Gregory Ginger, reports acquisition and disposal of common stock and restricted stock units.

EVP and Chief Legal Officer of Biogen, Susan H. Alexander, reports acquisition and disposal of common stock and restricted stock units.